ReviewSurgical oncology clinics of North America2017
Screening and Preventive Strategies in Esophagogastric Cancer.
Review in Surgical oncology clinics of North America, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 24 citations in OpenAlex.
- The global burden of oesophageal cancer from 1990 to 2023 and projections to 2040: a comprehensive analysis of the Global Burden of Disease Study 2023.Journal of global health · 2026Article
- Gender, racial, and stage-specific trends in esophageal cancer: Insights from longitudinal population data.World journal of gastrointestinal pathophysiology · 2025Article
- Global, regional, and national burden of esophageal cancer using the 2019 global burden of disease study.Scientific reports · 2025Article
- Survival improvements in esophageal and gastric cancers in the Nordic countries favor younger patients.Cancer medicine · 2024Article
- Oesophageal cancer cases recorded in the Zambia National Cancer Registry: a cross-sectional study.The Pan African medical journal · 2023Review
- Article
- The Use of miRNAs in Predicting Response to Neoadjuvant Therapy in Oesophageal Cancer.Cancers · 2022Review
- Advances in optical gastrointestinal endoscopy: a technical review.Molecular oncology · 2021Review
- Development of a clinical score to distinguish malignant from benign esophageal disease in an undiagnosed patient population referred to an esophageal diagnostic assessment program.Journal of thoracic disease · 2020Article
- Establish a Scoring Model for High-Risk Population of Gastric Cancer and Study on the Pattern of Opportunistic Screening.Gastroenterology research and practice · 2020Article
- CMIP is oncogenic in human gastric cancer cells.Molecular medicine reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Gastric adenocarcinoma, esophageal adenocarcinoma, and esophageal squamous cell carcinoma are among the most prevalent and deadly of malignancies worldwide. Screening and prevention programs will be critical to finally improving outcomes in these diseases. For gastric adenocarcinoma, screening in high-risk populations has significantly reduced mortality. More research is needed on screening high-risk individuals in low-risk populations. For esophageal adenocarcinoma, work is needed to develop efficient and effective techniques in mass screening programs. For most Western populations, current screening is not cost effective. Avoiding environmental risk factors is critical to reducing the incidence of this deadly illness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.